India, Nov. 16 -- Sanofi SA (SNY) announced the successful completion of negotiations with Canada's pan-Canadian Pharmaceutical Alliance (pCPA), marked by a signed Letter of Intent (LOI) for Sarclisa (isatuximab) in combination with bortezomib, lenalidomide and dexamethasone (VRd) as a first-line treatment for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Multiple myeloma is a blood cancer that develops in plasma cells, a type of white blood cell found in the bone marrow.
Although available treatments can control the disease, it remains incurable, and patients often experience relapse. Those who are not eligible for stem cell transplantation have a particular need for effective f...